immatics is developing new cancer drugs that help to activate specialized white blood cells of the patient’s immune system against cancer cells.

Our first product for the treatment of kidney cancer, IMA901, has entered a Europe-wide multi-center Phase II clinical trial in 2007. 

This page contains information on clinical trials sponsored by immatics and is provided for patients and healthcare professionals to increase the transparency of immatics' clinical development program.

Information contained within this website is not intended to replace any advice of a healthcare professional and must not be considered as a treatment recommendation. Patients should always seek professional and qualified medical advice before making any decisions on their treatment.

All reasonable precautions have been taken to ensure the accuracy of the information available through the site. immatics may amend the information at any time without notice.